Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission

BIO-PATH HOLDINGS, INC.

First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.
Patient is elderly female with gynecologic cancer, heavily pretreated with chemotherapy and surgeries.
Two elderly AML patients in Phase 2 triple combo (prexigebersen/decitabine/venetoclax) remain in complete remission: one at 16 cycles/21 months, another at 12 cycles/14 months.
Phase 1b of BP1001-A expected to begin after three monotherapy dose cohorts; will test combo with paclitaxel and gemcitabine.
Management highlights platform potential for targeted protein inhibition with favorable safety profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.